Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies? Academic Article Article uri icon


MeSH Major

  • Immunologic Deficiency Syndromes
  • Lung Diseases


  • In an attempt to clarify appropriate treatment options for women with stage IV breast cancer, we studied the survival experience of a large dataset of patients treated on Cancer and Leukemia Group B (CALGB) protocols. The study, restricted to women who had had no prior chemotherapy for metastatic disease, demonstrated a surprisingly poor prognosis, with an estimated median survival of 1.6 years and only 26% alive at 3 years. Analysis of prognostic factors permitted the identification of subsets with even shorter survival, such as women with estrogen receptor negative tumor in more than one metastatic site and prior adjuvant chemotherapy. We feel that an evaluation of intensive investigational treatment approaches, such as trials using autologous bone marrow transplantation, is justified for most stage IV breast cancer patients, in view of their poor prognosis.

publication date

  • January 1989



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1007/BF01806548

PubMed ID

  • 2650758

Additional Document Info

start page

  • 33

end page

  • 8


  • 13


  • 1